BioMarin drops VOXZOGO development for Noonan syndrome children
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq climbs over 1% as SpaceX, Super Micro improve AI sentiment
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Nvidia’s Huang highlights AI benefits in Berlin speech amid wider European tour
- AI bubble about to burst? Not yet, Yardeni says
Tweet
Share
E-mailBioMarin Pharmaceutical Inc. announced on September 15, 2026, that it will discontinue development of VOXZOGO for children with Noonan syndrome.
According to a company statement, the decision was based on an assessment of factors including study feasibility and the current treatment landscape for children with Noonan syndrome. BioMarin stated the decision was not related to the safety or efficacy of VOXZOGO.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Novartis wins EU approval for Cosentyx in rheumatic disease
- Showpad Announces Winners of the Second Annual Excellence in Action Awards
- ScalePad and Pax8 Announce Strategic Relationship
Create E-mail Alert Related Categories
Corporate News, FDA, Hot Corp. News, Hot FDA NewsRelated Entities
Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
